Insurance companies refuse to cover Wegovy for three overlapping reasons: federal law prohibits Medicare from paying for any drug prescribed for weight loss, most private plans and state Medicaid programs classify obesity medications as optional “lifestyle” treatments rather than essential benefits, and the combination of a roughly $1,349 monthly list price with an eligible population of about 100 million American adults makes broad coverage financially untenable for payers.1Medical News Today. Wegovy Cost2WebMD. Wegovy Insurance Cover Meds Those denials can sometimes be overturned, and there are growing workarounds, but the default answer from most insurers remains no.
Insurers Still Treat Obesity Drugs as Optional
Most denials trace back to a classification choice. Many plans categorize weight-loss medications as “lifestyle” or “vanity” drugs, grouping them with cosmetic treatments rather than therapies for chronic disease.2WebMD. Wegovy Insurance Cover Meds The American Medical Association recognized obesity as a disease in 2013, but that declaration carries no legal weight and compels no insurer, state, or federal program to pay for treatment.3National Center for Biotechnology Information. Obesity as a Disease Payers can accept the medical consensus and still exclude the drugs on cost grounds.
Why Medicare Won’t Pay for Wegovy
If you’re on Medicare, the barrier is written into federal statute. The 2003 law that created the Part D drug benefit explicitly prohibits Medicare from covering medications prescribed for “anorexia, weight loss, or weight gain.”4GoodRx. Does Medicare Cover Weight Loss Medication That exclusion has survived more than twenty years of changing medical opinion.
There is one practical exception. Wegovy holds a separate FDA approval for cardiovascular risk reduction in adults with established heart disease, and Part D plans may cover it for that purpose. Ozempic, which uses the same active ingredient, is covered when prescribed for type 2 diabetes.5healthinsurance.org. Does Health Insurance Cover Drugs Used for Weight Loss If the prescription is written for weight loss itself, Medicare will not pay.
Congress has considered the Treat and Reduce Obesity Act repeatedly, most recently as H.R. 4231 and S. 1973 in the 119th Congress, but none of these bills has passed.6Congress.gov. H.R. 4231 – Treat and Reduce Obesity Act of 20257Congress.gov. S. 1973 – Treat and Reduce Obesity Act of 2025 A New England Journal of Medicine study estimated that covering semaglutide for just 10% of Medicare beneficiaries with obesity would add $26.8 billion to annual program costs.8Vanderbilt University Medical Center. Medicare Antiobesity Medications9Centers for Medicare & Medicaid Services. Contract Year 2026 Policy and Technical Changes5healthinsurance.org. Does Health Insurance Cover Drugs Used for Weight Loss
The ACA and Medicaid Don’t Require Coverage
The Affordable Care Act requires plans to cover ten categories of essential health benefits, including prescription drugs, but weight-loss medications are not classified as essential health benefits under current federal guidelines. Insurers are not required to put them on formularies.5healthinsurance.org. Does Health Insurance Cover Drugs Used for Weight Loss Most state benchmark plans were set around 2017, before the current GLP-1 drugs reached the market.
Medicaid faces the same gap. Federal rules permit states to exclude weight-loss drugs from their formularies even when they must cover other FDA-approved medications. As of early 2026, only 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service arrangements, and several states that had offered coverage, including California, New Hampshire, Pennsylvania, and South Carolina, dropped it under budget pressure.10KFF. Medicaid Coverage of and Spending on GLP-1s
North Dakota became the first state to require coverage, amending its essential health benefits benchmark in January 2025 to force individual and small group plans to cover GLP-1s for diabetes prevention and the treatment of insulin resistance, metabolic syndrome, or morbid obesity.11Pharmacy Times. States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments Similar efforts in California, Montana, Texas, and New Mexico failed in 2025 and 2026.12LegiScan. AB 575 – Obesity Prevention Treatment Parity Act
Why Employer Plans Often Say No
Most Americans get insurance through work, and coverage there is uneven. A 2025 KFF employer survey found that only 19% of firms with 200 or more workers covered GLP-1s for weight loss, though the figure rose to 43% among employers with 5,000-plus workers.13KFF. Perspectives From Employers on the Costs and Issues Associated With Covering GLP-1 Agonists for Weight Loss A 2026 Business Group on Health survey of mostly large companies put coverage at 67%, but 10% of those employers planned to drop the benefit.14Business Group on Health. 2026 GLP-1 Survey
Self-insured plans, which cover the majority of American workers, are governed by federal ERISA law rather than state insurance mandates. That gives employers full discretion to exclude the drugs regardless of what any state says.5healthinsurance.org. Does Health Insurance Cover Drugs Used for Weight Loss
North Carolina’s experience shows the arithmetic that drives these decisions. The state health plan covers about 750,000 workers, retirees, and dependents. Spending on GLP-1s climbed from roughly $3 million per month in 2021–2022 to over $14 million per month in 2023, and officials projected annual costs would reach more than $1 billion by 2030 if coverage continued. The plan ended coverage for weight loss in April 2024 and had not restored it by mid-2026.15WRAL. North Carolina Expected Budget Won’t Restore Weight Loss Coverage16NC Treasurer. Treasurer Folwell and State Health Plan Issue Request for Information on GLP-1 Drugs
The underlying problem is that insurers routinely pay for drugs costing much more per patient, like cancer therapies, but those illnesses affect far fewer people. Obesity affects roughly 100 million American adults, and a 2025 JAMA Health Forum study concluded that at current net prices, semaglutide had a 0% probability of being cost-effective at standard thresholds; its price would need to drop by nearly 82% to meet the $100,000 per quality-adjusted life year threshold.17JAMA Network. Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults
Even “Covered” Doesn’t Mean Approved
When a plan does cover Wegovy, patients usually face prior authorization: a doctor must submit documentation justifying the treatment before the insurer agrees to pay. Among Medicare Part D plans, prior authorization requirements for these drugs jumped from 5% or fewer beneficiaries before 2024 to nearly 100% by 2025.18University of Pennsylvania LDI. Patients Face New Barriers for GLP-1 Drugs Like Wegovy and Ozempic
Common prior authorization criteria include:
- A BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension, type 2 diabetes, or high cholesterol.19SingleCare. Wegovy Prior Authorization Criteria Blue Cross Blue Shield
- Documentation of participation in a comprehensive weight management program, including behavioral modification, a reduced-calorie diet, and increased physical activity, typically for at least six months.20CVS Caremark. Wegovy Prior Authorization Criteria
- Step therapy requirements, meaning the patient must have tried and failed a non-GLP-1 weight-loss medication within the past six months.19SingleCare. Wegovy Prior Authorization Criteria Blue Cross Blue Shield
- Ongoing results: continued coverage may require at least a 5% reduction in baseline body weight after reaching the maintenance dose.20CVS Caremark. Wegovy Prior Authorization Criteria
Researchers at the University of Pennsylvania found that most current prior authorization policies are more restrictive than the FDA’s own prescribing criteria, often requiring documentation of multiple comorbidities beyond what the FDA label demands.18University of Pennsylvania LDI. Patients Face New Barriers for GLP-1 Drugs Like Wegovy and Ozempic
New Federal Pathways That May Help
Because Congress has not changed the statute, the Trump administration has opened two administrative channels for Medicare patients.
The Medicare GLP-1 Bridge program launched on July 1, 2026, and provides temporary access to Wegovy, Zepbound, and Foundayo for a fixed $50 monthly copay. The program operates outside the standard Part D benefit and is run by a central processor rather than individual plans. To qualify, you must be 18 or older with a BMI of 35 or higher; a BMI of 30 or higher with a condition like heart failure or chronic kidney disease; or a BMI of 27 or higher with pre-diabetes or a history of heart attack, stroke, or peripheral artery disease.21Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge – Information for Providers The $50 copay does not count toward Part D deductibles or out-of-pocket limits, and manufacturer financial assistance cannot be applied to it.22Medicare Rights Center. GLP-1 Weight Loss Drug Demonstration Begins July 2026
The longer-term BALANCE model is designed to run through December 2031. Under it, CMS negotiates GLP-1 prices directly with manufacturers; Novo Nordisk and Eli Lilly have agreed to a $245 net price per 30-day supply for Medicare. The Medicaid portion began accepting state applications in May 2026, but the Medicare Part D rollout originally scheduled for January 2027 has been delayed, and CMS has extended the Bridge program through December 2027 to fill the gap.23KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid24Becaris Publishing. Expanded Access to GLP-1 Medicines Hanging in the Balance as CMS Delays Medicare Rollout
Separately, the administration announced agreements in November 2025 to offer GLP-1 medications through a government website called TrumpRx at $350 per month, with oral GLP-1 formulations starting at $150 per month if approved by the FDA.25The American Journal of Managed Care. Trump Announces Deals With Eli Lilly, Novo Nordisk for Lower Weight Loss Drug Prices
How to Appeal a Wegovy Denial
For plans created after March 2010, you generally have six months from the denial notice to file an appeal.26Medical News Today. How to Appeal Wegovy Denial The process has three main steps.
Start by reading the Explanation of Benefits to identify the specific reason for denial. The reason matters: a denial based on medical necessity, formulary placement, or missing documentation is appealable in ways that an outright plan exclusion is not.
Next, ask your prescribing physician for a letter of medical necessity. A strong letter will document your BMI, your weight-related health conditions, your history of failed lifestyle interventions, and the clinical reasoning for Wegovy specifically.26Medical News Today. How to Appeal Wegovy Denial
If internal appeals fail, patients in fully insured plans can usually request an independent external review, typically within 365 days of the final internal decision.27Obesity Action Coalition. Appealing a Denial Based on 2023 data from ACA marketplace plans, about 44% of insurance denials were overturned on appeal.26Medical News Today. How to Appeal Wegovy Denial
One caveat: if your plan explicitly excludes weight-loss medications as a category, appeal rights may be limited. In that situation, patients with established cardiovascular disease may have better results asking the physician to prescribe Wegovy under its FDA-approved cardiovascular indication rather than for weight loss.
Paying Out of Pocket
If coverage is simply not available, Novo Nordisk runs several programs that cut the cost. Through NovoCare Pharmacy, self-pay patients can get Wegovy injections at $349 per month, or as low as $149 per month for lower-dose pills.28Sesame Care. Wegovy Cost Without Insurance Patients with commercial insurance may pay as little as $25 per month using a manufacturer savings card, though these cards cannot be used by anyone enrolled in government-funded insurance.29NovoCare. Wegovy Savings Offer
Uninsured patients with low incomes may qualify for the Novo Nordisk Patient Assistance Program, which provides the medication at no cost. Eligibility requires U.S. citizenship or legal residency, no enrollment in or eligibility for Medicaid or Medicare’s Low Income Subsidy, and household income at or below 400% of the federal poverty level. Approved patients are enrolled for 12 months and receive the medication shipped to their home.30NovoCare. Novo Nordisk Patient Assistance Program Without any discount, the list price stays near $1,349 for a 28-day supply.1Medical News Today. Wegovy Cost